Hymenoptera venom immunotherapy

Venom immunotherapy is a trigger-specific intervention for people with a qualifying systemic sting history and demonstrated sensitivity to the relevant insect venom. Repeated exposure to that allergen can alter venom-specific immune responses, including the development of blocking antibodies, but the current label says the mechanism of hyposensitization is not completely known. This is a different role from suppressing mast-cell activation across unrelated triggers.

A prospective study followed 84 people in Italy and Spain who had both systemic mastocytosis and Hymenoptera venom allergy while receiving venom immunotherapy. Ten treatment-course reactions were recorded during induction. Fifty participants later reported 95 field re-stings; 43 of those 50 reported no reaction, while seven reacted. Because there was no randomized comparison and field stings were not controlled, those observations cannot isolate a treatment effect or be generalized from systemic mastocytosis to MCAS.

The current U.S. label covers standardized honey-bee, wasp, hornet, yellow-jacket, and mixed-vespid venom products used according to the implicated sensitivity. It makes a prior significant systemic reaction plus positive diagnostic skin testing central to patient selection and places administration in a medically supervised setting prepared for a life-threatening reaction. The entry therefore appears under “Trigger-specific treatment” rather than in the numbered maintenance sequence.